Amgen Inc. closed 19.88% short of its 52-week high of $346.85, which the company reached on July 25th.

Amgen Inc . (NASDAQ:AMGN), a leading biopharmaceutical company with a market capitalization of $149 billion, is navigating a ...

Amgen (AMGN) ended the recent trading session at $277.88, demonstrating a +1.62% swing from the preceding day's closing price. The stock outperformed the S&P 500, which registered a daily gain of 0.53 ...

Amgen Inc (AMGN) stock saw a modest uptick, ending the day at $272.11 which represents a slight increase of $2.68 or 0.99% from the prior close of $269.43. The stock opened at $276.97 and touched a ...

Amgen's dividend profile shines, but growth slows. See why AMGN stock faces regulatory risks and offers limited incentives ...

Wells Fargo sees downside to Amgen’s (AMGN) 2025 consensus estimates, saying the company’ sales guidance could came in below expectations. It ...

Amgen has announced a $1 billion expansion in Holly Springs and has signed a dozen students from Wake Technical Community ...

Fortune Brands recently announced it will consolidate its U.S offices into one headquarters, taking over two of three office buildings previously owned by Horizon Therapeutics, then Amgen Inc., at ...

Amgen CEO Robert Bradway said the company's obesity drug could find its space in the market due to once-monthly dosing and ...

The U.S. Food and Drug Administration approved Amgen's combination therapy on Thursday to treat colorectal cancer in patients ...

Arcus Biosciences named former Amgen executive Richard Markus as its chief medical officer. The biopharmaceutical company, which is focused on cancer treatments, said Tuesday that Markus is scheduled ...

Amgen’s Lumakras and AstraZeneca’s Calquence are both in line to expand their respective oncology reaches with new FDA ...